Semaglutide
The once-weekly GLP-1 drug sold as Ozempic, Wegovy and Rybelsus. How it works, what the trials show, side effects and cost.
- FDA-approved since 2017
- 14.9% average weight loss in STEP 1
- Weekly shot or daily pill

Educational content only, not medical advice. Doses on this page come from FDA labels and clinical trials, not personal recommendations. Semaglutide is a prescription drug; talk to a licensed clinician.
Semaglutide at a glance
| Drug class | GLP-1 receptor agonist (a 31-amino-acid peptide) |
|---|---|
| Brand names | Ozempic (weekly shot, type 2 diabetes), Rybelsus (daily pill, type 2 diabetes), Wegovy (weekly shot or daily pill, weight management and heart risk) |
| How it is taken | Injection under the skin once a week, or a tablet once a day |
| Half-life | About one week |
| Main effects | Lower blood sugar, slower stomach emptying, less appetite |
| Status | FDA-approved Prescription only |
How semaglutide works
Semaglutide copies GLP-1, a hormone your gut releases after you eat. A small change to its structure lets it bind to albumin in the blood, so it lasts about a week instead of minutes.
- Appetite: acts on brain areas that control hunger and fullness, so people eat less.
- Digestion: slows how fast the stomach empties, which adds to fullness and causes much of the nausea.
- Blood sugar: helps the pancreas release insulin when glucose is high and lowers glucagon.
It does not burn fat directly. Weight comes off through a lower calorie intake, which is why protein and strength training matter for keeping muscle. See what is a peptide? for the basics.

What the research shows
Three trials that define semaglutide's benefits and limits.
1,961 adults with obesity or overweight took semaglutide 2.4 mg weekly for 68 weeks, with lifestyle advice. Stomach side effects were the most common and usually faded.
Wilding et al., NEJM 2021 (PMID 33567185)
17,604 adults with heart disease and overweight but no diabetes were followed for about 40 months. Events occurred in 6.5% on semaglutide vs 8.0% on placebo.
Lincoff et al., NEJM 2023 (PMID 37952131)
When treatment stopped, people regained about two-thirds of the weight they had lost within a year, and blood pressure and blood sugar gains largely reversed.
Wilding et al., Diabetes Obes Metab 2022 (PMID 35441470)
More context in peptides for fat loss and semaglutide vs tirzepatide.
Dosing on the FDA label
Semaglutide is started low and raised slowly, usually every four weeks, to limit stomach side effects. These are label schedules for reference only; your prescriber sets your dose. Convert any dose to syringe units with the semaglutide dosage calculator.
- Wegovy shot: 0.25 mg weekly, then 0.5 mg, 1 mg and 1.7 mg, up to a 2.4 mg maintenance dose. A 7.2 mg Wegovy HD option is also available.
- Ozempic shot: starts at 0.25 mg weekly, with maintenance doses of 0.5 mg, 1 mg or 2 mg.
- Pills: Rybelsus and the Wegovy pill are taken once daily on an empty stomach with a small sip of water, at least 30 minutes before food or other medicines.
Missed-dose rules differ between products, so check your label or ask your pharmacist. Use our fat loss calculator to set realistic expectations.
Side effects and warnings
- Common: nausea, diarrhea, vomiting, constipation, stomach pain, burping and tiredness, mostly while the dose is rising.
- Serious but less common: pancreatitis, gallbladder problems, kidney injury from dehydration, and low blood sugar when combined with insulin or sulfonylureas.
- Diabetic eye disease can worsen in people with type 2 diabetes, especially with fast drops in blood sugar.
- Boxed warning: thyroid C-cell tumors in rodents. Not for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
- Muscle loss: some of the weight lost is lean mass, so protein and resistance training matter.
For more, see peptide side effects and are peptides safe?

Compounding and cost
- Shortage over: the FDA declared the semaglutide shortage resolved on February 21, 2025. Grace periods ended April 22 for 503A pharmacies and May 22, 2025 for 503B outsourcing facilities.
- Safety reports: through May 31, 2026, the FDA received 990 adverse event reports for compounded semaglutide, including hospitalizations from dosing errors. It also warns against salt forms like semaglutide sodium.
- Research semaglutide sold online is not approved for human use and is not checked for identity, purity or sterility.
- Brand cost: Wegovy pens are $349 a month through the manufacturer's self-pay program ($199 for the first two low-dose fills through December 31, 2026), and the Wegovy pill is $149 to $299. Full breakdown in how much do peptides cost?
Read what is a compounded peptide? and the FDA's GLP-1 warning.

Semaglutide vs tirzepatide
Tirzepatide (Mounjaro, Zepbound) acts on two hormone receptors, GLP-1 and GIP, instead of one. In head-to-head and cross-trial comparisons it tends to produce more weight loss, with a similar side effect profile.
- Semaglutide: longest track record, proven heart benefit in SELECT, available as a pill.
- Tirzepatide: larger average weight loss in trials, injection only.
Full comparison: semaglutide vs tirzepatide. Track weight, labs and side effects over time with Lab Analysis.

Frequently asked questions
What is semaglutide?
Semaglutide is a GLP-1 receptor agonist, a peptide drug that copies the gut hormone GLP-1. It lowers blood sugar, slows stomach emptying and reduces appetite. It is FDA-approved as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for chronic weight management and lowering cardiovascular risk.
How much weight do people lose on semaglutide?
In the STEP 1 trial, adults with obesity or overweight taking semaglutide 2.4 mg weekly lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% on placebo, alongside diet and exercise advice. Results vary a lot from person to person.
What are the most common side effects of semaglutide?
Nausea, diarrhea, vomiting, constipation and stomach pain are the most common, especially when starting or raising the dose. Serious but less common risks include pancreatitis, gallbladder problems, kidney injury from dehydration and low blood sugar when combined with insulin or sulfonylureas. The label carries a boxed warning about thyroid C-cell tumors.
What happens when you stop taking semaglutide?
Most people regain weight. In the STEP 1 extension, participants regained about two-thirds of the weight they had lost within a year of stopping, and improvements in blood pressure and blood sugar largely reversed.
Is semaglutide a peptide?
Yes. Semaglutide is a 31-amino-acid peptide based on human GLP-1, with changes that let it bind to albumin in the blood. That is why it lasts about a week and can be taken once weekly.
Is compounded semaglutide still legal?
The FDA declared the semaglutide shortage resolved on February 21, 2025, and the grace periods for compounding pharmacies ended in April and May 2025. Pharmacies can no longer make essentially copies of the approved drug just because of a shortage, and the FDA has warned against salt forms such as semaglutide sodium. Compounded semaglutide is not FDA-approved.
How much does semaglutide cost?
As of October 2026, Wegovy pens cost $349 a month through the manufacturer's self-pay program, with a $199 introductory price for the first two fills of the lowest doses through December 31, 2026. The Wegovy pill costs $149 to $299 a month. Insurance may lower the cost when the drug is covered for your condition.
Who should not take semaglutide?
People with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not take it, and it is not recommended during pregnancy. Anyone with a history of pancreatitis, gallbladder disease, diabetic eye disease or kidney problems should discuss the risks with a clinician first.
Track your progress on a GLP-1
Log doses, weight and side effects, and upload bloodwork to see how your markers change over time. Free.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021. PMID 33567185
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023. PMID 37952131
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022. PMID 35441470
- U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. fda.gov
- Novo Nordisk. Save on Wegovy: self-pay prices. wegovy.com (checked October 29, 2026)
This content is for informational purposes only and is not medical advice. Semaglutide is a prescription medication. Always consult a qualified healthcare provider before starting, stopping or changing any medication.